Posts for Ticker ‘ENDP’

Top Analyst Upgrades and Downgrades (AGN, BJS, CTRN, ELN, ENDP, MVL, BTU, TXN, TXRH, TSN)

These are the top 10 analyst upgrades and downgrades we have seen from Wall Street firms early this Monday morning:

  • Allergan (AGN) Raised to Buy at Citigroup.
  • BJ Services (BJS) Cut to Underperform at Wells Fargo.
  • Citi Trends (CTRN) Cut to Neutral at JPMorgan.
  • Elan (ELN) Raised to Buy at UBS.
  • Endo Pharmaceuticals (ENDP) Started as Buy at Citigroup.
  • Marvel Entertainment (MVL) Cut to Neutral at Janney
  • Peabody Energy (BTU) Raised to Outperform at FBR.
  • Texas Instruments (TXN) Raised to Hold from Underperform at Jefferies; Reiterated Sell w/ $14 target at Auriga.
  • Texas Roadhouse (TXRH) Cut to Neutral at Baird.
  • Tyson Foods (TSN) Cut to Hold at Deutsche Bank.

Jon C. Ogg
July 20, 2009

Posted on: July 20, 2009 – 6:25 am in Analyst Calls, , , , , , , , , ,

Top Analyst Upgrades (AGN, CHU, ENDP, FLR, GD, LMT, MDZ, NETL, NUVA, SGR)

These are the top pre-market analyst upgrades and positive research calls we have seen from Wall Street this Tuesday morning:

Allergan (AGN) Raised to Overweight at Thomas Weisel.
China Unicom (CHU) Raised to Buy at UBS.
Endo Pharmaceuticals (ENDP) Started as Overweight at Thomas Weisel.
Fluor (FLR) Started as Outperform at Baird.
General Dynamics (GD) Started as Outperform at Morgan Keegan.
Lockheed Martin (LMT) Started as Outperform at Morgan Keegan.
MDS Inc. (MDZ) Raised to Buy at Jefferies.
NetLogic (NETL) Raised to Buy at Piper Jaffray.
Nuvasive (NUVA) Raised to Buy at Needham.
Shaw Group (SGR) Started as Outperform at Baird.

JON C. OGG

Posted on: June 2, 2009 – 6:36 am in Analyst Calls, , , , , , , , , ,

Top 10 Pre-Market Analyst Calls (NLY, CTV, ENDP, FSLR, HOV, JNY, OIIM, PDGI, V, YUM)

These are not all of the analyst calls affecting shares but these are ten that we are focused on this Thursday morning:

  • Annaly Mortgage (NYSE: NLY) cut to Hold at Citigroup.
  • CommScope (NYSE: CTV) Raised to Buy from Neutral at UBS.
  • Endo Pharmaceuticals Cut to Neutral at R.W. Baird.
  • First Solar (NASDAQ: FSLR) cut to Perform at Oppenheimer
  • Hovnanian (NYSE: HOV) cut to Sell at UBS.
  • Jones Apparel (NYSE: JNY) Raised to Buy from Hold at Lazard.
  • O2Micro (NASDAQ: OIIM) raised to Buy at Piper Jaffray.
  • PharmaNet Development (NASDAQ: PDGI) downgraded to Hold at Jefferies; downgraded to Neutral at R.W. Baird.
  • Visa (NYSE: V) Started as Equal-weight at Lehman Brothers.
  • YUM! Brands (NYSE: YUM) cut to Neutral at UBS.

Jon C. Ogg
May 1, 2008

Posted on: May 1, 2008 – 7:24 am in Analyst Calls, , , , , , , , , ,

Biotech Business Daily (BTRX, BMRN, DSCO, ENDP, MNKD, MIPI, QSC, TECH)

Today almost feels like the "March of Biotech-inguins" because most of the movers were small companies you might otherwise miss.  Here were the big movers:

  • Barrier Therapeutics (NASDAQ: BTRX) ran way up after first quarter results reported yesterday showed a 207% increase in revenues from last year at $8.4 million, driven by growth in sales of Vusion and Xolegel. Shares closed up 18% at $2.29 on a 52-week range of $1.90 to $7.60.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) showed a first quarter positive profit or $0.02 EPS on a net income of $1.7 million. Analysts expected losses of $0.05 EPS. Earnings were driven primarily by sales of enzyme replacement therapy Naglazyme. Shares closed up almost 8% at $36.46. The 52-week range is $15.99 to $41.00.
  • Discovery Labs (NASDAQ: DSCO) trading up in anticipation of FDA approval for lung surfactant, Surfaxin, a treatment for premature infants suffering from respiratory distress. The company communicated confidence that any regulatory concerns have been ironed out and this third FDA result will be positive. Shares rose 17% to $2.87. The 52-week range is $1.75 to $3.75.
  • Endo Pharmaceuticals (NASDAQ: ENDP) settled a proxy battle with shareholder D.E. Shaw by nominating William Spangler to the board. They posted earnings today showing a net income of $59.53 and $0.44 EPS. Shares closed down 0.7% at $24.83. The 52-week range is $22.62 to $35.85.
  • Mannkind Corporation (NASDAQ: MNKD) up over 16% in anticipation of earnings release Monday. Shares up $0.37 at $2.60 at the close. The 52-week range is $1.86 to $14.71.
  • Molecular Insight Pharma (NASDAQ: MIPI) up almost 7% today on no news, although some just may be the thin volume and wide bid/ask spread. The oncology molecular imaging pharmaceutical company is sitting at $7.83 on a 52-week range of $5.66 to $12.95.
  • Questcor (AMEX: QSC) down despite posting strong first quarter results showing a positive net income of $6.5 million compared to a loss of $3.8 in first quarter 2007. The company also amended agreement Acthar distribution discount prices, positively impacting Questcor cash flows. Shares closed down 2.5% at $4.24. The 52-week range is $0.21 to $6.60.
  • Techne Corp. (NASDAQ: TECH) up after third quarter profit jumped 24% to $29.6 million or $0.76 EPS, beating estimates. Shares closed at $72.52, up 1%, on a 52-week range of $54.49 to $72.00.

Rachel Lopez
April 30, 2008

Posted on: April 30, 2008 – 3:21 pm in Biotech, Newsletter, , , , , , , ,

Penwest Pharmaceuticals (PPCO) Set For Huge Fall

According to The Associated Press Endo Pharmaceuticals (ENDP). and Penwest Pharmaceuticals (PPCO). said Wednesday the patent on their pain drug Opana ER is being challenged by Impax Laboratories Inc.

Endo and Penwest are currently reviewing the details of this notice from IMPAX. Endo and Penwest note that they intend to pursue all available legal and regulatory avenues in defense of OPANA® ER, including enforcement of their intellectual property rights and approved labeling.

PPCO is off 31% in the pre-market at a 52-week low of $7.85.

Douglas A. McIntyre

Posted on: October 4, 2007 – 7:33 am in Biotech, ,